USPTO serial 79314660
CELLIXIR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 24, 2024
- Examiner
- COUGHLAN, REBECCA D.
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CELLIXIR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mary Margaret L. O'Donnell
Mary Margaret L. O'Donnell Blue Filament Law PLLC700 E. MapleSuite 450Birmingham, MI 48009Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals and biochemical products for industrial and scientific use and not for medical or veterinary use, for transferring biological molecules into living cells and for integrating foreign nucleic acids into the genome of living cells; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposes, for the transfer of chemical or biological molecules into living cells and the integration of foreign nucleic acids into the genome of living cells; biological preparations for laboratory use, other than for medical and veterinary use; diagnostic preparations, other than for medical and veterinary use; peptide substrates, protein arrays and nucleic acids or complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes for clinical or medical laboratory use, for identifying genetic expression and protein location and integration of foreign nucleic acids into the genome of living cells; chemical and biochemical preparations for industrial and scientific use; chemical and biochemical soluble substances and solutions for industrial use and not for medical or veterinary purposes, for cellular and gene engineering and analysis in laboratories; Chemicals, namely, standard solutions and buffers used in analytical chemistry for transferring chemical and biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and transient production of proteins or nucleic acids; aqueous chemical and biochemical solutions containing nutrients for cultivating living cells for use in electroporation; biological cell and tissue cultures for laboratory use other than for medical and veterinary use; diagnostic reagents other than for medical and veterinary use; peptide substrates, protein array and nucleic acids or complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for clinical or medical laboratory use, in particular for detecting and monitoring, and for integrating foreign nucleic acids into the genome of living cells and transient production of proteins; transfection reagents in the nature of chemical and biochemical reagents, used for transient production of proteins, other than for medical and veterinary use | ACTIVE | — |
| 005 | Pharmaceutical and veterinary preparations, namely, cells, tissues, and grafts engineering reagent for medical or veterinary purposes; diagnostic preparations for medical and veterinary use; living cells and cultures of microorganisms as well as protein arrays, synthetic peptides for the treatment of blood, genetic, and immune disorders and cancer and nucleic acid sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and veterinary use; living cells and cultures of microorganisms as well as proteins arrays, synthetic peptides and nucleic acids sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and clinical use for the treatment of genetic defects in gene therapy, viral and infectious diseases, cardiovascular diseases and cancer; diagnostic preparations for medical and veterinary use, in particular for the diagnosis and analysis of genetic defects, viral and infectious diseases, cardiovascular diseases and cancer; living cells, cultures of microorganisms, and proteins arrays, synthetic peptides and nucleic acids sequences and complexes of these molecules, namely, ribo-nucleo and desoxyribo-nucleo complexes, nucleo-proteo complexes for medical and veterinary use, in particular for medical and clinical use for the treatment of genetic defects in gene therapy, viral and infectious diseases, cardiovascular diseases and cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 27, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 10, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 9, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 24, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 24, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 24, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 5, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 5, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 16, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 30, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 30, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 30, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 30, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 30, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 4, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 4, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 4, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 14, 2024 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 18, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 10, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 26, 2023 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Dec 27, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 7, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 7, 2022 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jun 12, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 26, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 25, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 25, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 25, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 25, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 25, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 25, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 25, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 23, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 29, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 29, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 28, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 27, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 10, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 6, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 1, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |